A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
Janssen · Salivary Gland Neoplasms
Phase 2
Active, not recruiting
31
2026-07
Industry sponsor intelligence
JanssenClinical Pipeline.
Lead-sponsor view of Janssen's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 4
- Recruiting
- 0
- Active
- 2
- Completed
- 2
- Results posted
- 1
- Avg enrollment
- 362
Pipeline overview
Programs by phase and activity.
Velocity
Janssen trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 10
Phase 21
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Goserelin → | 2 | 0 | 1 | 1 | 0 | 2 |
| Leuprolide → | 1 | 0 | 0 | 1 | 0 | 1 |
| Triptorelin → | 1 | 0 | 0 | 1 | 0 | 1 |
| Albiglutide → | 1 | 0 | 0 | 0 | 0 | 0 |
| Degarelix → | 1 | 0 | 0 | 0 | 0 | 0 |
| Dulaglutide → | 1 | 0 | 0 | 0 | 0 | 0 |
| Exenatide → | 1 | 0 | 0 | 0 | 0 | 0 |
| Liraglutide → | 1 | 0 | 0 | 0 | 0 | 0 |
| Lixisenatide → | 1 | 0 | 0 | 0 | 0 | 0 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Janssen · Prostatic Neoplasms
Phase 3
Active, not recruiting
692
2026-07
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen · Prostatic Neoplasms
Not applicable
Completed
979
2025-12
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Janssen · Diabetes Mellitus, Type 2 · Cardiovascular Diseases
Not applicable
Completed
714,582
2025-06
Search sponsor records
All Janssen studies.
This page groups studies where Janssen is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
4 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT04325828A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland CarcinomaJul 6, 2026NCT04557059A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate CancerJul 6, 2026NCT04034095A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in JapanDec 15, 2025NCT03492580A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular DiseaseJun 25, 2025